43rd NANOS Annual Meeting (North American Neuro-Ophthalmology Society)
GenSight gave an oral presentation and presented two posters on its lead product GS010 currently in Phase 3 in Europe and US aiming at treating LHON, a rare mitochondrial genetic disease
Both posters were presented at the session “Poster Session II: Scientific Advancements in Neuro-Ophthalmology” in the Category: Disorders of the Anterior Visual Pathway (Retina, Optic Nerve, and Chiasm) on Tuesday, April 4, 2017 from 6:00 -9:30 pm, Room Location: Exhibit Hall C
Title: Pediatric Leber Hereditary Optic Neuropathy (LHON): A Literature Review (Poster Number # 186)
Title: Preliminary Baseline Characteristics of Patients with LHON Enrolled in RESCUE and REVERSE Gene Therapy Trials (Poster Number # 189)
Presentation took place on Tuesday, April 4th from 10:00am- 10:15am, in the Thurgood Marshall Ballroom
Title: Phase I/IIa Visual Acuity Outcomes 1.5-Years Post-Treatment with rAAV2/2-ND4, Investigational Gene Therapy for ND4 LHON.